SOX30 and acute myeloid leukemia: In non-M3 AML and CN-AML, patients with SOX30 hypermethylation tended to have lower CR rate than those with SOX30 non-hypermethylation [44% (30/68) vs 31% (23/74), P = 0.121 and 54% (20/37) vs 33% (15/45), P = 0.074].